Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Domain Therapeutics

Request full access

Committed to improve patients’ life and to support physicians by delivering innovative immunotherapies to fight cancer

Illkirch, FranceFounded 2001Biotech & Life Sciences

About Domain Therapeutics

Domain Therapeutics is a biopharmaceutical startup that is focused on developing innovative cancer treatments. The company's primary area of research is GPCR (G protein-coupled receptors) mediated-immunosuppression. In simpler terms, they are working on drugs that can help the immune system fight against tumors more effectively.

The company's pipeline includes a variety of potential treatments, some of which are in Phase I of clinical trials. These include an A2aR/A2bR antagonist (M1069) and an EP4 receptor antagonist (DT-9081). They also have a couple of candidates in the discovery phase, including an anti-CCR8 antibody (DT-7012) and a PAR2 antagonist (DT-9045).

Domain Therapeutics operates in the biotech market, specifically in the oncology sector. Their business model revolves around the research, development, and eventual commercialization of their cancer treatments. They make money by progressing their treatments through the various phases of clinical trials, with the aim of eventually selling these treatments to healthcare providers and patients.

The company serves a broad range of clients, including healthcare providers, patients, and other stakeholders in the healthcare industry. They are committed to advancing multiple first-in-class and best-in-class programs to tackle GPCR-mediated immunosuppression in immune-oncology.

Source: Dealroom company data

At a glance

Status
Operational
Employees
36
Open positions
None listed
Dealroom signal
62.9/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Oncology, Spinout, Arts & Culture, Biotech and Pharma, radar de l'innovation, observatoire industrial tech, proteomics, DT and LS, observatoire healthtech
Business model
Manufacturing
Investment activity
3 companies, latest Mar 2020
Capital deployed
$6.9M
Preferred round
ACQUISITION

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANTOther financing Jan 2024 $11M — Undisclosed ↗
SERIES AOther financing May 2022 $42M $168M Turenne Capital · Seventure Partners · Omnes Capital · Schroders ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Domain Therapeutics website traffic

Latest recorded traffic for Domain Therapeutics is 3.6K monthly website visits, up 50% over the last three months. Domain Therapeutics's team declined 46.3% over the past year.

Latest monthly visits3.6K 3-month web change+50% 1-year team growth-46.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Domain Therapeutics in the Illkirch ecosystem

Live from Dealroom

The Domain Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A13 investors entered at this stage

  • Sofinnova Partners
  • Auriga Partners
  • Bpifrance
  • Seventure Partners
  • CTI Life Sciences
  • 3B Future Health Fund
  • Turenne Capital
  • Omnes Capital
  • Schroders
  • AdMare BioInnovations
  • Viva BioInnovator
  • Panacea Venture
  • Seido Capital

Other known investors1 additional known investor

  • French National Centre for Scientific Research - CNRS
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇫🇷 France81.3%
🇨🇦 Canada9.4%
🇬🇧 United Kingdom3.1%
🇨🇭 Switzerland3.1%
🏳️ Monaco3.1%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Domain Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Domain Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.